. 2018 Apr 9;7(5):R196–R211. doi: 10.1530/EC-18-0079
This work is licensed under a Table 4.
Dysthyroidism induced by PD-L1 Ab according to pathology type.
| Study (authors and publication year) | Study phase (or name) | Number of patients | Pathology | Treatment | Hypothyroidism (%) | Hyperthyroidism (%) | Thyroiditis (%) |
|---|---|---|---|---|---|---|---|
| Herbst et al. (2014) (71) | Phase 1 | 277 | Multiple types of advanced cancers (melanoma, RCC, NSCLC, CRC, GC and HNSCC, etc.) | Atezolizumab i.v. 0.1–20 mg/kg/3 weeks | NR | NR | NR |
| Fehrenbacher et al. (2016) (49) | Phase II trial (POPLAR) | 277 | Previously treated, advanced or metastatic NSCLC | Atezolizumab i.v. 1200 mg/3 weeks (142 patients) docetaxel 75 mg/m2/3 weeks (135 patients) | 6/0 | NR | NR |
| Rosenberg et al. (2016) (50) | Phase 2 trial | 310 | Inoperable locally advanced or metastatic urothelial carcinoma which progressed after previous platinum-based chemotherapy | Atezolizumab i.v. 1200 mg/3 weeks | NR | NR | NR |
| Peters et al. (2017) (52) | Phase II trial (BIRCH) | 659 | Advanced-stage NSCLC, no CNS metastases, with or without prior chemotherapy | Atezolizumab i.v. 1200 mg/3 weeks first line; n = 139; second line; n = 268; third line or higher n = 252 | 5 | NR | NR |
| Rittmeyer et al. (2017) (54) | Phase III trial (OAK) | 850 | Stage IIIB or IV NSCLC with one to two previous cytotoxic chemotherapy regimens with ≥1 platinum-based combination therapies | 1:1 (425 patients for each group) i.v. atezolizumab 1200 mg or docetaxel 75 mg/m2 every 3 weeks | NR | NR | NR |
| Balar et al. (2017) (51) | Phase 2 trial (IMvigor210) | 119 | Locally advanced or metastatic urothelial cancer which were cisplatin-ineligible | Atezolizumab i.v. 1200 mg/3 weeks | 8 | NR | NR |
| Gulley et al. (2017) (61) | Phase 1b (JAVELIN Solid Tumor) | 184 | Advanced, platinum-treated NSCLC | Avelumab i.v. monotherapy 10 mg/kg every 2 weeks | 6 | NR | NR |
| Antonia et al. (2016) (62) | Phase 1b study | 102 | Locally advanced or metastatic NSCLC | Durvalumab i.v. 3, 10, 15, or 20 mg/kg q4w or 10 mg/kg q2w were combined with tremelimumab 1, 3, or 10 mg/kg q4w for six doses then q12w for three doses | 10 | NR | NR |
| Powles et al. (2017) (65) | Phase 1/2 study | 191 | Locally advanced/metastatic UC with disease progression, or ineligibility for or refusal for prior chemotherapy | Durvalumab i.v. 10 mg/kg q2w | 5.2 | 5.2 | NR |
ALK, anaplastic lymphoma kinase; AUC, area under curve; EGFR, epidermal growth factor receptor; GC, gastric cancer; HNSCC, head and neck squamous cell carcinoma; ICC, investigator’s choice of chemotherapy; i.v., intravenous; NCSLC, non-small-cell lung cancer; NR, not reported; q2w, every 2 weeks; q4w, every 4 weeks; RCC, renal cell carcinoma; SCC, squamous cell carcinoma; UC, urothelial cancer.